Scope Biosciences has raised €6 million in follow-up funding to further its CRISPR-based molecular diagnostics platform, scopeDx. With a total of €6 million in seed-stage funding, including strategic capital and grants, the company aims to improve diagnostics in agriculture and healthcare. The portable, field-ready technology enables precise detection directly at the source without centralized labs, offering significant advantages in both sectors. The growing demand for point-of-care testing solutions underscores the importance of Scope Biosciences in addressing real-world diagnostic needs, particularly where laboratory facilities are insufficient.
Scope Biosciences has secured €6 million to advance its CRISPR-based diagnostics platform, aiming for more effective detection technology for agriculture and healthcare.
The funding round illustrates significant investor confidence in Scope Biosciences’ progress and its potential to revolutionize molecular diagnostics through portable technology.
ScopeDx allows for ultra-precise detection of diseases without needing centralized labs, enhancing early detection capabilities in both agriculture and healthcare.
As demand for point-of-care testing rises, Scope Biosciences targets challenges in real-world diagnostics, combining advanced CRISPR technology with practical deployment solutions.
Collection
[
|
...
]